Alex Gustafson

Gen Surg Resident @YaleSurgRes | Former Immunotherapy and Surgical Oncology Research Fellow @NCI_CCR_SB | @GUMedicine 2020 | @BU_tweets 2014

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: "Correlation between recognition of autologous tumor organoids by tumor-infiltrating lymphocytes from metastatic epithelial cancers and clinical response" https://t.co/iOED3XEoco
@nicholasklemen @slgoff_SB

[Alex Gustafson @AlexGustafsonMD]

One third of identified drivers are non-canonical!
HLA LOH seen in many hot spot loci —> informs immunotherapy response and TCR based treatment eligibility 🧬

[Cancer Cell @Cancer_Cell]

Online Now: Cancer type-specific variation in patterns of driver alterations across 50,000 tumors https://t.co/lEDBg7Mw4y

[Brandon Luu, MD @BrandonLuuMD]

For breast cancer, alternative medicine alone was linked to a 267% higher mortality hazard.

Even when combined with standard treatment, mortality hazard was still 45% higher.

Modern oncology saves lives. Please consider using it.

[Alex Gustafson @AlexGustafsonMD]

@stewartwjames Nicest thing you’ve ever said about me

[Alex Gustafson @AlexGustafsonMD]

6 yrs ago I opened my match email and was disappointed.
I made the best of it creating lifelong friends, spent time at NCI, and eventually switched residencies. Success isn’t always linear, but I’m so incredibly happy where I am today. Things have a way of working out. #match2026

[Alex Gustafson @AlexGustafsonMD]

Always excited to talk TIL therapy!

[Yale Cancer Center @YaleCancer]

At #SSO2026, @AlexGustafsonMD shares research showing that testing a patient’s immune cells against tumor organoids, or lab-grown versions of their own tumor, may help predict patient response to TIL therapy. @SocSurgOnc @OncoAlert @SmilowCancer

[Lindsay Friedman, MD, MS @lindSLUeMD]

Love a @NCI_SurgOncFel reunion
@SocSurgOnc ! Forever thankful for
@NCICCR_SurgOnc for the opportunity to make lifelong friends and colleagues across the country.

What an honor to know and grow with the future of SSO!

@AnnSurgOncol #SSO2026

[Alex Gustafson @AlexGustafsonMD]

First intra-lesional immunotherapy! Love hearing about the roots of immuno-oncology @SocSurgOnc @gmboland
#SSO2026

[Yale Cancer Center @YaleCancer]

Dr. Nicole Aguirre presents research findings on characterizing germline variants in peritoneal surface malignancies (PSM) of appendiceal origin during a #SSO2026 poster session today at 3pm MST.
@SmilowCancer @YaleGICancers @SocSurgOnc

[NEJM @NEJM]

In a phase 1 study of the oral p53 reactivator rezatapopt in heavily pretreated patients with TP53 Y220C–mutated solid tumors, the most common adverse events were nausea and vomiting, and the overall response was 20%. Full PYNNACLE study results: https://t.co/LBqROGlouc

Science behind the Study: Restoring Function to a Variant of p53 in Solid Tumors https://t.co/5Ox6Kuax6Q

[Alex Gustafson @AlexGustafsonMD]

This is incredible

[Mohamed Eltemamy @moeltemamy]

First in the world SP Robotic Kidney Pancreas tx:
- Both grafts placed on the left side
- K anast time: 33 min
- P anast time: 45 min
- Op time: 5h33m
- LOS: 4 days
@CleClinicUro @amjtransplant @ASTSChimera @AmerUrological @AmCollSurgeons @IHPBA @EAHPBA @AHPBA #Robotics

[Alex Gustafson @AlexGustafsonMD]

Great overview of progress made in the development of immunotherapies for cancer. So much potential for future treatment options!

[Chrystal Paulos @Chrystal_Paulos]

3: This roadmap highlights next-gen constructs:
Armored CAR & TCR cells
Bispecific & trispecific antibodies
Immune-stimulatory antibody conjugates (ISACs)
In vivo gene editing
AI-driven engineering
It’s a blueprint for transformative cures.

[Alex Gustafson @AlexGustafsonMD]

@jigdeneve @JoseTrevinoMD @UNCSurgery @UNC_Lineberger @SocSurgOnc @FreudenbergerMD @VCU_Surgery @VCUGenSurgRes Congrats @FreudenbergerMD !!!

[Journal of Clinical Oncology @JCO_ASCO]

Adoptive Cell Transfer of Tumor-Infiltrating Lymphocytes for Metastatic Acral Lentiginous Melanoma. Co-authored by @AlexGustafsonMD and @nicholasklemen.

Read full article. https://t.co/TfPrvmWlRc

[Nature Medicine @NatureMedicine]

In a phase 2 trial, patients with metastatic, treatment-refractory #gastrointestinal cancers responded to neoantigen-reactive tumor-infiltrating #lymphocytes, not bulk ones, showing promise for refined immune cell therapy. #ImmuneTherapy #Neoantigens
https://t.co/8bSOrM3mf9

[Annie Geller, MD PhD @AnneEGeller]

Funding from the @NIH contributed to the development of 354 out of 356 (99.4%) of the new drugs approved by the FDA between 2010 and 2019, and 🚨 100% 🚨 of FDA approved drugs btw 2010-2016. @NIH funding is the backbone of American biomedical innovation. #protecttheNIH

[Alex Gustafson @AlexGustafsonMD]

@HHSGov @SecKennedy How do you propose “doing really good unimpeded science” if you’ve blocked funding to the federal agencies and prohibited communication with the public? @SecKennedy @realDonaldTrump

[nature @Nature]

About a month after Donald Trump took office as the 47th US president, almost all grant-review meetings remain suspended at the US National Institutes of Health (NIH), preventing the world’s largest public funder of biomedical research from spending much of its US$47 billion annual budget.

https://t.co/ly8mKijdtQ

[Alex Gustafson @AlexGustafsonMD]

That’s a wrap on #SITC2024! Great showing by @NCI_CCR_SB

[Stephanie L Goff, MD, FACS @slgoff_SB]

A little bit of #SITC24. On the tail end of four days in Houston. @NCI_CCR_SB #TIL for melanoma and more! Photo courtesy of the long arms of @adinerman1990 @AlexGustafsonMD